Product Description
Fluorouracil is part of a group of chemotherapy drugs known as anti metabolites. Anti metabolites are similar to normal body molecules but they have a slightly different structure.Fluorouracil is also known as FU or 5FU and is one of the most commonly used drugs to treat cancer. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/fluorouracil)
Mechanisms of Action: TS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Keratosis | Keratosis, Actinic
Known Adverse Events: Erythema | Keratosis | Pruritus | Keratosis, Actinic | Edema
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Mexico, Peru, Poland, Portugal, Romania, Russia, Singapore, Spain, Taiwan, Turkey, United Kingdom, United States
Active Clinical Trial Count: 31
Highest Development Phases
Phase 3: Adenocarcinoma|Bladder Cancer|Breast Cancer|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Keratosis, Actinic|Muscle Cancer|Nasopharyngeal Cancer|Pancreatic Cancer|Squamous Cell Carcinoma
Phase 2: Anus Cancer|Bile Duct Cancer|Biliary Tract Cancer|Ductal Carcinoma|Hepatocellular Carcinoma|Islet Cell Carcinoma|Neuroendocrine Carcinoma|Pancreatic Ductal Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AndroMETa-GEA | P2 |
Recruiting |
Esophageal Cancer|Gastrointestinal Cancer|Adenocarcinoma |
2030-10-01 |
|
| Rad-IO | P3 |
Unknown status |
Bladder Cancer|Muscle Cancer |
2030-02-07 |
|
| NPC-Nivo | P2 |
Unknown Status |
Nasopharyngeal Cancer |
2028-08-31 |
|
| M24-311 | P2 |
Unknown Status |
Colorectal Cancer |
2026-10-01 |